Tumours are frequently characterised by series of cytogenetic abnormalities. Amplifications of the human telomerase gene hTERC (3q26) and myelocytomatosis-C proto-oncogene MYCC (8q24) have been associated with cervical intraepithelial neoplasia (CIN) and carcinoma of the uterine cervix. The results of genetic analysis allow to select patients at high risk of progression from CIN to carcinoma. Our group conducted a study in which the chromosomal abnormalities found in the cytology specimens of 26 patients with either cervical cancer or CIN were analysed using the recently developed triple-colour human papillomavirus-fluorescence in situ hybridisation (HPV-FISH) assay. HPV infection was proven in 22 (85 %) patients. Amplification of MYCC and hTERC was found in 11 (42 %) and 16 (62 %) patients, respectively. Based on these results, the patients were divided into high-risk, medium-risk and low-risk groups.
The genetic basis of progression from CIN I to CIN II/III and on to invasive carcinoma is poorly understood. Although infection with high-risk human papillomavirus (HPV) is recognised as an essential initiating event in cervical tumourigenesis, 4 this alone is not sufficient to explain the progression to invasive cancer. A number of cell regulators are involved in the process. Certain chromosomal aberrations have been associated with the progression of CIN to carcinoma, especially the amplification of the human telomerase gene hTERC (3q26) and the myelocytomatosis-C proto-oncogene MYCC (8q24); 5, 6 hTERC is involved in the maintenance of chromosomes by providing telomerase stability and regulating telomerase length; MYCC is a transcription factor that participates in cell proliferation and differentiation. specific genes enables to assess the copy number of these genes on a cell-by-cell basis and thus provides information about the heterogeneity in the tumour. In addition, the detection of these cells when present at low frequency may be prognostically important.
Advances in molecular cytogenetics techniques have enabled the study of genomic alterations as biomarkers of progression during uterine tumourigenesis. This is the basis of the rationale for the development of a specific FISH assay intented as a cytogenetic diagnostic tool for the direct detection of HPV-infected cells and alterations of selected genes in cytology specimens (HPV-FISH).
Recently, a new FISH probe kit was designed to identify HPV-infected cells and determine copy number changes for hTERC and MYCC in pre-neoplastic lesions and cervical carcinomas. 8, 9 In a study conducted by our group at Masaryk University in Brno (Czech Republic), the cytology specimens of 26 women with a histologically confirmed diagnosis of either CIN or cervical cancer were evaluated alongside routinely collected cytology samples (Pap smears) using the new HPV-FISH assay, and the cytogenetic findings were compared with the histological diagnoses. We also set the prognostic risk for each patient according to recommended settings.
Patients and Methods

Cervical Specimens
Cervical specimens were obtained from the Department of 
Slide Pre-treatment and Hybridisation
Slide pre-treatment and FISH were performed according to the manufacturer's protocol. Slides were briefly soaked in 2X saline sodium citrate (SSC) buffer at 73°C for two minutes and then incubated in pepsin (0.5 mg/ml in 10 mmol/l hydrochloric acid)
at 37°C for 10 minutes. They were than soaked in 1X phosphate buffered saline (PBS) at room temperature for five minutes, fixed in 1 % neutral-buffered formalin at room temperature for five minutes, and finally soaked in 1X PBS at room temperature for another five minutes.
Slides were dehydrated using 70 %, then 80 % and 96 % ethanol for one minute before air drying. The probe mixture (10 μl) was then applied and the slides and probe were co-denatured at 72°C for two minutes and hybridised at 37°C overnight. After hybridisation, the slides were washed in 2X SSC at 48°C for two minutes and then in 2X SSC at room temperature for one minute.
Detection of Human Papillomavirus Using Tyramide Signal Amplification Assay
Detection of the biotin-labelled HPV probes was performed using an Alexa Fluor ® 488 TSA kit (Invitrogen/Life Technologies, Carlsbad, US)
according to the directions given in the Vysis Cervical FISH Probe Kit.
The slides were incubated in 3 % hydrogen peroxide at room temperature for 30 minutes to block endogenous peroxidase activity and then soaked in 1X PBS at room temperature for five minutes.
Prior to application of streptavidin-HRP (SA-HRP) conjugate (diluted 1:100 in blocking reagent), the slides were incubated with 1 % blocking reagent in PBS (both incubations were performed in a humified chamber at 37°C for 25 minutes). After washing the slides three times in 1X PBS at 37°C for five minutes, the biotin-labelled HPV probe-SA-HRP complex was visualised by incubation with Alexa hTERC and MYCC Amplification in Cervical Intraepithelial Neoplasia and Cervical Carcinoma Fluor 488 labelled tyramide (1:100 dilution) for 10 minutes at room temperature. The slides were then washed three times in 1X PBS at 37°C for five minutes and diamidino-2-phenylindole (DAPI) nuclear counterstain was applied.
Slide Analysis
The slides were analysed under an Olympus BX-61 ® fluorescence microscope equipped with a CCD-1300D ® Vosskühler camera and LUCIA-KARYO/FISH/CGH ® imaging system (Laboratory Imaging, Czech Republic) using 40x and 100x magnification and DAPI with green, gold and red single bandpass filter sets. In all cases, the entire hybridised surface area was analysed. Cells were evaluated according to the Vysis Cervical FISH Probe Kit directions.
Classification Algorithm
A green filter was used to visualise HPV staining, its localisation in the nucleus was confirmed by DAPI staining. The staining pattern was classified as diffuse or punctate (see Figure 2 ), as described in previous studies. 8, 9 The sample was considered positive for HPV Patients were classified as low-risk, medium-risk or high-risk according to the HPV and chromosomal findings (see Figure 3) .
Results
The results regarding the numbers of patients with HPV-positive cells and chromosomal abnormalities, and the risk assessment for patients with CIN or cervical cancer are summarised in Tables 1 and 2 .
HIV-positive cells were found in 22 of 26 patients (85 %). Three of nine patients with pre-malignant lesions (CIN I, CIN II and CIN III) were found to be HPV-negative; only one patient (with carcinoma in situ) of the 17 with cervical cancer was found to be HPV-negative.
Original Contribution 15 This specific genetic abnormality was also found in pre-malignant CIN II/CIN III and is thought to be a genetic aberration that occurs in the early stages of tumour development. As such, it has value for predicting malignant transformation and disease progression. 14, 16, 17 Another specific genetic abnormality linked to the development of cervical carcinoma is MYCC amplification. Golijow et al. 5 showed that there is a difference in the number of MYCC copies in CIN I, CIN II/CIN III and carcinoma in situ, suggesting that the amplification of MYCC is important not only in tumour progression, but also in cell transformation during pre-invasive stages.
B: HPV-positive cell (green spots) without chromosomal aberrations in hTERC (only two yellow spots) and MYCC (only two red spots): case classified as medium-risk. C: HPV-negative cell (no green spots) with chromosomal aberrations in hTERC (more than two yellow spots) and MYCC (more than two red spots): patient classified as high-risk. D: HPV-negative cell (no green spots) without chromosomal aberrations in hTERC (only two yellow spots) and MYCC (only two red spots): patient classified as low-risk. FISH = fluorescence in situ hybridisation; HPV = human papillomavirus.
+ = HPV cells or chromosomal abnormality or LVSI present; -= HPV cells or chromosomal abnormality or LVSI not present. HPV = human papillomavirus; HR = high risk; LVSI = lymphovascular space invasion; LR = low risk; MR = medium risk; TNM = tumour, node, metastasis (classification system of malignant tumours).
Discussion
The principal aim of our study was to optimise the HPV-FISH assay classification. 8 In our study, we found diffuse staining (episomal HPV) only in one CIN III case and in some carcinoma cases; however, our group of patients was too small to draw any conclusions about this.
In our study, the incidence of hTERC amplification was higher than that of MYCC amplification (62 % and 42 %, respectively). In patients with pre-malignant lesions, MYCC and hTERC copy number changes were found in three of nine cases (44 %), all of whom had CIN III histology. In patients with tumours, hTERC amplification was found in hTERC and MYCC Amplification in Cervical Intraepithelial Neoplasia and Cervical Carcinoma 13 of 17 cases (76 %) and MYCC amplification in eight cases (47 %).
An increase of 3q24-28 has been shown to be the most frequent chromosomal aberration in cervical cancer: more than 85 % of invasive cervical carcinoma feature this change. 6 Other studies have shown that an increase in the 3q chromosome arm is the most common aberration, not only in invasive carcinoma, but also in CIN II, CIN III and carcinoma in situ. [17] [18] [19] [20] Using FISH, amplification of hTERC was detected in only some cytologically normal or CIN I cases, but in 62. and to invasive cervical carcinoma. 6, 16, 17 In accordance with these studies, we only found amplification of hTERC in CIN III pre-malignant cases and in the majority of invasive cancers. Our results confirm that the vast majority of invasive cervical carcinomas carry extra copies of hTERC.
In our study, amplification of hTERC in all three CIN III pre-malignant cases was attended by MYCC amplification. Golijow et al. 5 have shown significant differences in the degree of MYCC amplification between cytologically normal and abnormal pre-cancerous specimens. Their study also showed higher numbers of MYCC with increased histological classification and confirmed the important role of this gene in pre-malignant cell transformation.
We found a higher incidence of MYCC increase in patients with tumours -eight of them (47 %) had MYCC alterations. Using immunohistochemical techniques, Brenna et al. 21 detected a similar In our study, MYCC changes were also noted predominantly in patients with stage IB and IIIB tumours, supporting the theory of a role for MYCC in the later stages of cervical tumourogenesis.
By scoring the HPV staining and chromosomal changes, we were able to divide patients into high-risk, medium-risk and low-risk groups.
These groups may predict the risk of progression or regression, especially in the pre-malignancy stages. Patients with CIN I and CIN II were defined as low-or medium-risk. Only three patients with CIN III histology were classified in the high-risk group; all of them had both hTERC and MYCC amplification.
Among the 17 patients with cervical cancer, only one (with carcinoma in situ) was classified as being low-risk, because of the absence of HPV-infected cells. Three of the 12 patients with stage IB cancer were defined as being medium-risk. The other nine patients with stage IB cancer, as well as the other patient with carcinoma in situ and all three patients with stage IIIB tumours were categorised as high-risk.
Due to a short clinical follow-up, no statistical analysis of cervical cancer progression was conducted for patients with aberrations (we plan to prospectively follow-up participants for five years after diagnosis). However, six patients were positive for LVSI; all of them were high-risk and had hTERC amplification, and two also had MYCC amplification. Based on these results, we suggest that high-risk patients would require more frequent follow-up and aggressive therapy.
Conclusions
Recent advances in molecular genetics and cytogenetics have Original Contribution
